Viewing Study NCT01519661

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:59 AM
Ignite Modification Date: 2026-05-21 @ 9:24 PM
Study NCT ID: NCT01519661
Status: COMPLETED
Last Update Posted: 2015-02-10
First Post: 2012-01-24
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Pulmonary Infections View
None Pseudomonas Aeruginosa in Cystic Fibrosis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Tobramycin Inhalation powder View
None Cystic fibrosis View
None Lung disease View
None Anti-bacterial agents View